Suchergebnisse - "Liang, Zhaoduan"

PubPharm (26)

1

STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells

enthalten in: Cell death & disease | 2024

von Wang, L. | Liang, Z. | Guo, Y. | +15

2

MODIFIED CELL AND USE THEREOF

enthalten in: Europäisches Patentamt | 2024

von LIANG ZHAODUAN | TIAN YE | LI ZHENJUAN | +1

3

T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity

enthalten in: Cell reports | 2023

von Cui, Y. | Yuan, T. | Wang, Y. | +21

4

A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors

enthalten in: Nature communications | 2023

von Li, D. | Chen, C. | Li, J. | +17

5

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells

enthalten in: Frontiers in immunology | 2023

von Liang, Z. | Chen, W. | Guo, Y. | +7

6

Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma

enthalten in: Immunology | 2023

von Chen, L. | Liu, S. | Adah, D. | +4

7

Tumor-specific polypeptide, T cell receptor for recognizing same and application of tumor-specific polypeptide and T cell receptor

enthalten in: Europäisches Patentamt | 2022

von DONG XUAN | LIANG ZHAODUAN | QIN LILI | +5

8

High-affinity and soluble PDL-1 molecule

enthalten in: Europäisches Patentamt | 2021

von LI YI | LIANG ZHAODUAN

9

HIGH-AFFINITY AND SOLUBLE PDL-1 MOLECULE

enthalten in: Europäisches Patentamt | 2021

von LI YI | LIANG ZHAODUAN

10

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

enthalten in: Journal for immunotherapy of cancer | 2020

von Liu, Q. | Tian, Y. | Li, Y. | +9